Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years…
The world’s biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
Continue reading Pfizer Earnings Top Estimates, Boosts Guidance
…
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more sa…
Big Pharma didn’t rest Thursday, with Celgene, Sanofi-Aventis and AstraZeneca among the big names reporting earnings. A deal between Stryker and Boston Scientific and Sanofi and BMP Sunstone also made the headlines, as did some…